Figure 1
From: EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

Effects of lenvatinib on the MAPK signaling pathway in HCC cells. (A,B) Lenvatinib was added at concentrations of 0, 1, and 3 μM in medium containing 10% fetal bovine serum for 1, 4, and 24 h, respectively. Lenvatinib downregulated ERK phosphorylation in Hep3B cells (A) and Huh7 cells (B). (C) Lenvatinib at 3 µM for 4 h downregulated ERK phosphorylation in JHH-4 and Huh6 cells. (D) Lenvatinib at 3 µM for 4 h did not downregulate ERK phosphorylation in HepG2 cells. In all experiments, immunoblotting of phosphorylated ERK (p-ERK), ERK, and internal controls (ACTB or TUBB) levels was performed. The intensity with the internal control were indicated. At least two times of the independent experiments of (A-D) were performed and representative results were shown.